Trial Profile
Phase 3 study of S-888711 in thrombocytopenic patients with chronic liver disease
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 05 Jul 2023
Price :
$35
*
At a glance
- Drugs Lusutrombopag (Primary)
- Indications Thrombocytopenia
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms L-PLUS1
- Sponsors Shionogi
- 30 Jun 2023 According to a Shionogi media release, the Mulpleta (Lusutrombopag), has received approval from the Center for Drug Evaluation, NMPA for treatment of thrombocytopenia in adult patients with chronic liver disease (CLD) who are scheduled to undergo a procedure.
- 19 May 2020 Results of post hoc analysis assessing the efficacy and safety of lusutrombopag in patients undergoing a GI procedure published in Gastroenterology in conjunction with Digestive Disease Week 2020
- 11 Dec 2019 According to a Shionogi media release, the company today announce that the National Institute for Health and Care Excellence (NICE) and Scottish Medicines Consortium (SMC) have published positive appraisals recommending the use of Mulpleo (lusutrombopag) by the NHS in England, Wales and Scotland for the treatment of severe thrombocytopenia in adult patients with chronic liver disease (CLD) undergoing planned invasive procedures based on L-PLUS1 and L-PLUS2